Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
BASELINE HIGH RENAL RESISTANCE INDEX IS ASSOCIATED WITH WORSENING OF RENAL FUNCTION IN PATIENTS UNDERGOING CARDIAC SURGERY
Anno:
2023
Renal resistance index (RRI) is a parameter which is easily evaluable by the echo Doppler technique and which has been demonstrated to predict worsening of renal function (WRF) in patients affected by chronic heart failure as well as among those undergoing coronary angiography. The aim of this study was…
THREE-DIMENSIONAL RIGHT VENTRICULAR ARTERIAL COUPLING IN HEART FAILURE: PROGNOSTIC COMPARISON WITH TRADITIONAL METHODS
Anno:
2023
Background: Right ventricular (RV) contractile function and pulmonary artery (PA) pressures influence outcomes in patients with heart failure (HF). Analysis of RV-arterial coupling (RVAC) from pressure-volume loops is not routinely performed. Several non-invasive RVAC methods by echocardiography have been described in patients with HF. The aim of this study was…
Multi-Institutional Italian Experience of Atrial Flow Regulator Device in Congenital and Acquired Heart Disease
Anno:
2023
The Atrial Flow Regulator is a self-expandable nitinol device implanted into the interatrial septum to establish a communication with a predetermined diameter.The creation of such shunt is advisable in several cardiovascular diseases.In pediatric population,the experience is limited to a few case reports describing patients with failing Fontan,pulmonary hypertension,or severe heart…
WORSENING OF RENAL FUNCTION AND INCREASE IN RENAL RESISTANCE INDEX AFTER CARDIAC SURGERY
Anno:
2023
Worsening of renal function (WRF) is frequently observed after cardiac surgery and it is associated with both short- and long-term worse outcome. Among the pathophysiological conditions favoring the occurrence of WRF, the abnormalities in renal blood flow could play a key role. The aim of this study was to…
HEART FAILURE DURING ACUTE CORONARY SYNDROME AND THE LONG-TERM RISK OF INCIDENT CANCER. THE ABC-9* STUDY ON HEART DISEASE.
Anno:
2023
Introduction: Recent reports have suggested a higher risk of incident cancer among patients with pre-existing Heart failure (HF) in community-based cohorts. Methods: To investigate the association between heart failure (HF) during hospitalization with acute coronary syndrome (ACS) and the very long-term cancer risk, we enrolled 572 patients admitted with…
Left ventricular outflow tract velocity-time integral (LVOT-VTI) improves risk stratification in heart failure patients with secondary mitral regurgitation
Anno:
2023
Background: Reduced left ventricular ejection fraction (LVEF) has been used as a key criterion for the management of mitral regurgitation (MR) in patients with heart failure (HF), including the decision about mitral valve repair. However, LVEF, not taking into account mitral regurgitant volume, may be an imprecise predictor of…
THE ROLE OF BIOELECTRICAL PHASE ANGLE IN PATIENTS WITH HEART FAILURE
Anno:
2023
The most challenging feature of heart failure (HF) still remains the evaluation of congestion. Residual congestion at discharge and the difficulties in perfectly dosing therapies in order to balance the hydration status of the patient are the most worrisome issues when dealing with HF. The use of bioimpedance vector…
Does cardiac amyloidosis ever hide a severe aortic stenosis A case report
Anno:
2023
Case presentation: A 89-year-old man, with an history of paroxysmal atrial fibrillation and chronic renal disease, was admitted to our ER for acute decompensated heart failure. He reported dyspnea on minimal exertion and worsening peripheral edema. He had a history of heart failure and a severe aortic stenosis first diagnosed in 2020…
SIDE EFFECTS OF SGLT-2 INHIBITORS IN PATIENTS WITH HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Anno:
2023
Background: sodium-glucose cotransoporter-2 inhibitors (SGLT-2Is) improve prognosis in heart failure patients both with reduced (HFrEF) and preserved ejection fraction (HFpEF). However, these drugs can have some side effects. Purpose: estimate the relative risk of side effects in HF patients treated with SGLT-2Is irrespectively from left ventricular EF and setting…
Dapagliflozin use in HFrEF patients: a single centre comparison between real-life and DAPA-HF data
Anno:
2023
Background: Practice guidelines recommend Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) for patients with heart failure with reduced ejection fraction (HFrEF). Our study aimed to describe our population of patients with indications for Dapagliflozin, to compare it with the DAPA-HF trial population and assess the possible prognostic evolution. Methods: We retrospectively analysed…